Details of the Drug
General Information of Drug (ID: DM52NOI)
Drug Name |
NSC-656158
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
CHM-1; NSC-656158; 154554-41-3; CHM 1; CHM-1 hydrate; CHEMBL280099; 6-(2-Fluorophenyl)[1,3]dioxolo[4,5-G]quinolin-8(5h)-One; 1,3-Dioxolo[4,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; NSC656158; AC1Q4OOR; AC1L8C3G; Neuro_000375; SCHEMBL338729; CTK7C2351; AOB2618; DTXSID80327429; MolPort-009-194-114; HMS3262E04; ZINC5581788; KS-00002WS1; Tox21_500741; BDBM50041119; AKOS015994545; LP00741; CE-0108; NCGC00261426-01; NCGC00186026-01; NCI60_019422; J-009113; 1,5-g]quinolin-8(5H)-one, 6-(2-fluorophenyl)-; BRD-K94145482-001-02-8
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 283.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||